Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trialLiulu Zhang, Kun Wang, Ciqiu Yang et al.|Cell Reports Medicine|2025Cited by 9